CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 185 enrolled
Drug / intervention
ladiratuzumab vedotin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03310957
NCT03310957Phase 2Completed
CompareCT.gov

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Seagen Inc.·interventional·Posted Oct 16, 2017·Updated Dec 12, 2025

In Brief

A Phase 2 clinical trial evaluating ladiratuzumab vedotin and Pembrolizumab for Triple Negative Breast Neoplasms. Completed, enrolled 185 participants across 50 sites in 4 countries.

Detailed Summary

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs. A side effect is anything the drugs do besides treating cancer. Pembrolizumab is a drug that can be used to treat triple-negative breast cancer. The trial will also find out if these drugs work to treat this type of cancer. Participants in this study have metastatic breast cancer. This means the cancer has spread to other parts of the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple Negative Breast Neoplasms
CountriesGermany, South Korea, Spain, United States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 16, 2017
Enrollment StartFeb 27, 2018
Primary CompletionSep 30, 2024
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 8.7 years ago

Interventions

ladiratuzumab vedotindrug

Given into the vein (IV; intravenously)

Pembrolizumabdrug

IV infusion every 3 weeks